ICECURE MEDICAL LTD
ICCMNASDAQ🏆 #3701 by market capUS Equity
$774.68▼ $46.09 (−5.95%)
Simulated price1h—
24h▼ 6.0%
7d—
14d—
30d—
1y—
🏦Market Cap
$9M
Small Cap
📈Revenue Growth (YoY)
+8.9%
Slowing
📊Gross Margin
36.5%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
2.6x
Cheap
Otter Score
45
Weak
No chart data available for ICCM.
Trading Snapshot
- Day Range
- $768.61 – $785.66
- 52-Week Range
- $2.12 – $42.00
- Volume
- $3.09B
- Avg Volume
- $3.33B
- Shares Outstanding
- 3.4M
- Next Earnings
- Oct 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $856,535
- P/E Ratio
- —
- P/S Ratio
- 2.6x
- EPS (TTM)
- $-5.33
- Dividend Yield
- —
Why Investors Own ICCM
- ✓High-growth profile — revenue up +49.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$4M▲ +50.0% YoY
Gross Margin (TTM)
44.7%▲ +2.5% YoY
Operating Income (TTM)
$290,976▲ +50.0% YoY
Free Cash Flow (TTM)
$416,706▲ +50.0% YoY
About ICECURE MEDICAL LTD
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for the women's health and oncology markets. The company is headquartered in Caesarea, Israel.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
45/100
Analyst Price Target
ⓘAverage Target
$796.68
▲ +2.8% Upside
High Target$898.53
Low Target$632.72
Based on 31 analysts
Latest News & Updates
🚀
CNBC·2h ago
ICECURE MEDICAL LTD tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift ICCM price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
ICECURE MEDICAL LTD announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.